Medical Condition News

RSS

Qureight closes $20 million Series B financing

Qureight, an end-to-end imaging company that provides enterprise-grade imaging and precision endpoints for clinical trials with a focus on lung and heart disease, today announced it has raised $20 million in a Series B financing, led by Molten Ventures.

From Qureight 30 Jul 2026

When sleep changes in women over 80, it may signal more than aging

Researchers tracked sleep-wake changes over five years in 704 women in their 80s and 90s using wrist actigraphy. Declining nighttime sleep and increasing 24-hour sleepiness were associated with approximately twice the hazard of all-cause mortality.

29 Jul 2026

Discovery of calcium channel mechanism offers clues for brain disorder treatments

DGIST (President Kunwoo Lee) announced that a research team led by Professor Byung Chang Suh of the Department of Brain Sciences has, for the first time, uncovered a novel molecular mechanism that regulates the "N-type voltage-gated calcium channel (CaV2.2)," which plays a critical role in neural signal transmission.

29 Jul 2026

Combination therapy improves progression-free survival in dMMR/MSI-H metastatic colorectal cancer

Patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer experienced a 58% reduction in the risk of disease progression or death when treated with atezolizumab plus modified FOLFOX6 and bevacizumab compared with atezolizumab alone, according to results from the NRG-GI004/SWOG S1610 COMMIT trial published recently in the Journal of Clinical Oncology.

29 Jul 2026

Controlled breathing shows promise for reducing substance use cravings

Controlled breathing interventions can reduce cravings in people who use substances, including alcohol, tobacco, and other drugs, according to a new review published in the scientific journal Addiction.

29 Jul 2026

ALS risk varies significantly across U.S. military service branches

Compared to Army veterans, men who are veterans of the U.S. Air Force, Navy and Coast Guard have higher rates of amyotrophic lateral sclerosis (ALS), and men who are Marine veterans have lower rates, according to a new study published July 29, 2026, in Neurology®, an official journal of the American Academy of Neurology.

29 Jul 2026

Low-fat diet lowers dietary glycation compounds for years in postmenopausal women

Researchers analyzing dietary data from 40,209 postmenopausal women found that a low-fat pattern emphasizing fruits, vegetables, and grains was associated with sustained reductions in estimated dietary advanced glycation end-product intake over approximately seven years. The findings suggest broad dietary changes may lower dAGE intake without specific cooking instructions, although the study did not measure biological AGE exposure or determine whether the reductions influenced breast cancer outcomes.

29 Jul 2026

Early-life sugar restriction may reduce dementia risk later

Consuming less sugar in utero before birth and during the first one to two years of life was associated with a lower risk of developing dementia later in life, according to a study published July 29, 2026, in Neurology, the medical journal of the American Academy of Neurology.

29 Jul 2026

Researchers train AI to detect diabetes and assign four diagnostic labels

Researchers developed a two-stage machine learning framework that detected diabetes and classified records as prediabetes, type 1, type 2, or type 3c diabetes using two public datasets. XGBoost showed strong internal performance, but inconsistent model rankings, non-standard variables, and the absence of external clinical validation limit immediate use.

29 Jul 2026

Study questions antihistamine use for managing eczema symptoms

Adding oral antihistamines to existing eczema treatments is unlikely to lead to clinically important reductions in eczema and itch severity, and may not reduce sleep disturbance or flare-ups, finds a review of the latest trial evidence published by The BMJ today.

29 Jul 2026

Researchers find potential pathway to improve glioblastoma treatment

New research published in Neuro-Oncology gives a glimpse at promising discoveries that could help shape the future of glioblastoma treatment and patient outcomes.

29 Jul 2026

Wildfire evacuation triggered long-term mental health impacts for LA residents

Los Angeles County residents living in evacuation warning or order zones during the 2025 wildfires experienced heightened levels of anxiety and depression almost a year later, according to new USC research.

29 Jul 2026

Immature NK cells in donor cord blood can undermine CAR NK cell therapy activity

The composition of donor cord blood may play a critical role in the success of chimeric antigen receptor (CAR) natural killer (NK) cell therapies.

29 Jul 2026

New home test uses thigh length to detect type 2 diabetes or prediabetes

A new home test can detect type 2 diabetes or prediabetes with high accuracy. The test has been developed using artificial intelligence and large amounts of health data – and surprisingly, one of the steps involves measuring the length of your thigh.

29 Jul 2026

Deramiocel cell therapy slows muscle and heart damage in advanced DMD

A cell therapy called deramiocel could slow muscle weakening in boys and young men with advanced Duchenne muscular dystrophy (DMD), and may also slow heart damage in those who already have heart muscle disease, a phase 3 clinical trial published in The Lancet has found.

29 Jul 2026

ACLM launches Project Remission to shift the goal of chronic disease care

The American College of Lifestyle Medicine (ACLM) today announced the launch of Project Remission, a call to action to shift the goal of chronic disease care from symptom management to the possibility of achieving remission and health restoration.

29 Jul 2026

FDA grants fast track designation to Insilico's AI-designed mesothelioma drug candidate

Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced that ISM6331, a novel, potential best-in-class pan-TEAD inhibitor driven by Insilico's proprietary AI, has received Fast Track Designation (FTD) from the U.S.

29 Jul 2026